Mifepristone Oral: Dosing and Precautions
Mifepristone guidance for termination of intra-uterine pregnancy up to 22 weeks when combined with misoprostol.
Also searched as
Source reviewed
source date listed on the source page
Guide category
Oral drugs
Safety boundary
Prescription medicine information for clinician-guided use.
Kenza Health Hub presents this medicine page as structured health education. Check dose, route, interactions, pregnancy or breast-feeding considerations, and local protocol with a qualified clinician or pharmacist. Read our medical editorial policy.
Therapeutic action
Antiprogestogen.
Indications
Termination of intra-uterine pregnancy up to 22 weeks after the last menstrual period, in combination with misoprostol.
Forms and strengths
- 200 mg tablet.
Dose and duration
- 200 mg single dose, followed by the administration of misoprostol 1 to 2 days later.
Contra-indications, adverse effects, precautions
- Do not administer to patients with chronic adrenal failure or severe uncontrolled asthma.
- May cause gastrointestinal disturbances, vaginal bleeding, uterine contractions, and headache.
- Breast-feeding: no contra-indication for a single dose; avoid if multiple doses are required.
- Do not use mifepristone in ectopic or molar pregnancy.
Source
MSF Essential drugs practical guidelines (January 2026)
This page combines source-derived medicine reference sections with Kenza editorial context, while leaving out the Storage and Remarks sections from the source batch.
Rate this guide
Be the first to rate this guide.